摘要:
An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid.
摘要翻译:特异性结合sFlt-1或其片段的分离的抗体,其具有(i)包含SEQ ID NO:2的氨基酸序列的可变重结构域,(ii)包含SEQ ID NO:2的氨基酸序列的可变轻区域区域 SEQ ID NO:4,或(iii)(i)和(ii)两者,药物组合物和包含这种抗体的试剂盒,制备这种抗体的方法,确定sFlt- 1或其片段,治疗或预防性地需要sFlt-1拮抗剂的方法,分离的核酸,其包含编码(i)SEQ ID NO:1的氨基酸序列的核苷酸序列, 2,(ii)SEQ ID NO:4或(iii)(i)和(ii),任选地作为载体的一部分,以及包含并表达这种核酸的宿主细胞。
摘要:
An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid.
摘要翻译:特异性结合sFlt-1或其片段的分离的抗体,其具有(i)包含SEQ ID NO:2的氨基酸序列的可变重结构域,(ii)包含SEQ ID NO:2的氨基酸序列的可变轻区域区域 SEQ ID NO:4,或(iii)(i)和(ii)两者,药物组合物和包含这种抗体的试剂盒,制备这种抗体的方法,确定sFlt- 1或其片段,治疗或预防性地需要sFlt-1拮抗剂的方法,分离的核酸,其包含编码(i)SEQ ID NO:1的氨基酸序列的核苷酸序列, 2,(ii)SEQ ID NO:4或(iii)(i)和(ii),任选地作为载体的一部分,以及包含并表达这种核酸的宿主细胞。
摘要:
The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.
摘要:
The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.
摘要:
The present invention relates to antibodies that immunospecifically bind to human brain natriuretic peptide or a human brain natriuretic peptide fragment with a high binding affinity, methods for producing and selecting said antibodies, immunoassays for human brain natriuretic peptide or a human brain natriuretic peptide fragment that employ said antibodies and therapeutic compositions containing said antibodies.
摘要:
The present invention relates to antibodies that specifically bind to human BNP and immunoassays using said antibodies in the quantification of human BNP or a fragment of human BNP in a test sample.
摘要:
The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.